课题基金 / 基金详情

IMMUNITY TO MELANOMA WITH IL-2-SECRETING ALLOGENEIC CELL

IMMUNITY TO MELANOMA WITH IL-2-SECRETING ALLOGENEIC CELL
分泌 IL-2 的同种异体细胞对黑色素瘤具有免疫力
批准号:
2096763
负责人:
EDWARD P. COHEN
金额:
$13.3万
依托单位国家:
美国
项目类别:
财政年份:
1992
资助国家:
美国
项目状态:
已结题
起止时间:
1992-04-03 至 1995-03-31

项目摘要

项目成果

EDWARD P. COHEN的其他基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
In spite of the fact that they express immunogenic determinants, B16 melanoma cells grow progressively in immunocompetent C57BL/6 mice (H-2b). The mechanism of "escape" is not established. Since cytotoxic T lymphocytes are known to recognize an extraordinarily wide array of small peptides (in the context of histocompatibility class I), including neoantigens associated with malignant cells, it may be that the growth of antigeneic tumors results from a failure of immune recognition, not from the absence of tumor associated determinants. An understanding of the cellular "defect" that enables tumor cells to grow in immunocompetent recipients could have important implications for the specific immunotherapy of cancer. As an experimental approach, we used transfection to construct IL-2-secreting, allogeneic mouse fibroblasts that express melanoma associated antigens. We then tested the cells' immunogenic properties in terms of their ability to elicit an anti melanoma immune response in mice syngeneic with the tumor. The construct was prepared by transfecting genomic DNA from B16 cells (H-2b) into LM cells (H-2k) which are allogeneic with C57BL/6 mice. Colonies of transfected cells expressing melanoma- associated determinants were isolated, and then infected with an expression competent plasmid carrying the gene for IL-2. In our experiments, C57BL/6 mice rejecting the IL-2-secreting, melanoma antigen-positive allogeneic mouse cells developed cellular immunity to the melanoma. This immunity exceeded that following immunization with non-IL-2-secreting constructs, or with B16 cells. The objectives of the proposal are to determine the specific cell types activated for rejection of B16 melanoma following immunization of C57BL/6 mice with the IL-2-secreting cell constructs, and compare them with cell types activated following immunization of mice with constructs that lack one or more of the immunogenic properties. In addition, we plan to determine if exogenous IL-2 can substitute for the direct cell-to-cell (paracrine) transfer of IL-2 in the induction of an anti melanoma immune response. Finally, we plan to determine if immunizations of tumor-bearing mice with the IL-2-secreting constructs leads to increased survival.
期刊论文(9)
专著(0)
科研奖励(0)
会议论文
Interleukin-2-secreting mouse fibroblasts transfected with genomic DNA from murine melanoma cells prolong the survival of mice with melanoma.
用鼠黑色素瘤细胞的基因组 DNA 转染分泌白细胞介素 2 的小鼠成纤维细胞,可延长患有黑色素瘤的小鼠的存活时间。
DOI: --
发表时间: 1994
期刊: Cancer research
影响因子: 11.2
作者: [Kim,TS, Cohen,EP]
通讯作者: Cohen,EP
Independent cell types are involved in the induction of antimelanoma responses in C57BL/6 mice immunized with interleukin-2-secreting allogeneic mouse fibroblasts expressing melanoma-associated antigens.
在用表达黑色素瘤相关抗原的分泌白细胞介素 2 的同种异体小鼠成纤维细胞免疫的 C57BL/6 小鼠中,独立的细胞类型参与诱导抗黑色素瘤反应。
DOI: 10.1097/00002371-199311000-00008
发表时间: 1993
期刊: Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy
影响因子: --
作者: [Kim,TS, Collins,MK, Cohen,EP]
通讯作者: Cohen,EP
Neoplastic cells that express low levels of MHC class I determinants escape host immunity.
表达低水平 MHC I 类决定簇的肿瘤细胞逃避宿主免疫。
DOI: --
发表时间: 1994
期刊: Seminars in cancer biology
影响因子: 14.5
作者: [Cohen,EP, Kim,TS]
通讯作者: Kim,TS
MHC antigen expression by melanomas recovered from mice treated with allogeneic mouse fibroblasts genetically modified for interleukin-2 secretion and the expression of melanoma-associated antigens.
黑色素瘤的 MHC 抗原表达是从用同种异体小鼠成纤维细胞处理的小鼠中恢复的,该小鼠成纤维细胞经过基因改造,可分泌白细胞介素 2 并表达黑色素瘤相关抗原。
DOI: 10.1007/bf01525640
发表时间: 1994
期刊: Cancer immunology, immunotherapy : CII
影响因子: --
作者: [Kim,TS, Cohen,EP]
通讯作者: Cohen,EP
6
    DNA-based Vaccine for Treatment of Oral Carcinoma
    DNA-based Vaccine for Treatment of Oral Carcinoma
    DNA-based Vaccine for Treatment of Oral Carcinoma
    DNA-based Vaccine for Treatment of Oral Carcinoma